Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. 1996

A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
Cardiorenal Research Laboratory, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

Endothelin (ET) is a potent vasoconstrictor peptide which is elevated in plasma in congestive heart failure. Recent studies suggest an important role for angiotensin II (AII) in the activation of ET in cultured cardiomyocytes. Chronic thoracic inferior vena caval constriction (TIVCC) is a model of reduced cardiac output that mimics the neurohumoral activation observed in congestive heart failure. We hypothesized that activation of the renin-angiotensin system in TIVCC plays a role in the activation of ET and that the elevation of endogenous ET contributes to the systemic and renal vasoconstriction that characterizes this model of venous congestion. We studied conscious dogs after 7 d of TIVCC in the presence or absence of chronic angiotensin converting enzyme inhibition with enalapril. TIVCC resulted in marked activation of plasma AII and ET in plasma, right atrium, lung, and renal medulla which was further localized to cardiomyocytes, pulmonary, and renal epithelial cells. Chronic angiotensin converting enzyme inhibition abolished the increases in plasma AII and ET during TIVCC. Acute endothelin A receptor blockade with FR-139317 resulted in significant decreases in mean arterial pressure and systemic vascular resistance in TIVCC. We conclude that activation of the renin-angiotensin system contributes to the activation of circulating and local ET in TIVCC and that this activation plays an important role in the regulation of arterial pressure and systemic vascular resistance in this model of congestive failure.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D014682 Vena Cava, Inferior The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs. Inferior Vena Cava,Inferior Vena Cavas,Vena Cavas, Inferior

Related Publications

A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
September 1992, The American journal of physiology,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
February 1988, Circulation research,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
December 1993, The American journal of physiology,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
March 1998, Journal of hypertension,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
December 1973, The American journal of physiology,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
November 2004, Journal of cardiovascular pharmacology,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
December 2002, Hypertension (Dallas, Tex. : 1979),
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
October 1996, The Annals of thoracic surgery,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
March 2002, Transplantation,
A L Clavell, and M T Mattingly, and T L Stevens, and A Nir, and S Wright, and L L Aarhus, and D M Heublein, and J C Burnett
November 2004, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!